Diagnosing China's impact on patients, policy and the future of global health.
The go-to newsletter & podcast for policymakers, investors, biopharma & medtech industry, and public health leaders.
Now the decline of this niche has driven out everybody else I can be on it. I am doing this also because my generalist editor will filter technicalities out.
Covering the priorities of both the leadership and the general public in China and views you do not normally see from mainstream English-language media